Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above

A Phase II, Randomized, Placebo-controlled, Observer-blind, Multi Center Study on the Safety and Immunogenicity of Novartis Tetravalent Influenza Vaccine (Containing Both Interpandemic Strains and H5N1) in Adults Aged 18 Years and Above

Evaluate the immune response and reactogenicity of H5N1 vaccination in adults aged 18 years and above (as part of a tetravalent vaccine)

Inclusion Criteria:

• Healthy subjects (aged 18 years and above) who have signed an informed consent form

Exclusion Criteria:

• Any acute or chronic illness
• Receipt of seasonal influenza vaccine for the current season 2007/2008
• Known or suspected impairment/alteration of immune function
• Receipt of another vaccine within 3 weeks prior to Visit 1 or planned vaccination within 3 weeks following the last study vaccination
• Any serious disease
• Hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein,neomycin or kanamycin or any other component of the study vaccine
• Receipt of blood, blood products or immunoglobulins 3 months prior to vaccination